Henshaw R C, Templeton A A
Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen Maternity Hospital.
Br J Obstet Gynaecol. 1991 Oct;98(10):1025-30. doi: 10.1111/j.1471-0528.1991.tb15341.x.
To compare the effectiveness of 200 mg mifepristone with 1 mg gemeprost vaginal pessary in achieving cervical dilatation and softening ('priming') before late first trimester pregnancy vacuum aspiration.
A randomized, operator blind, placebo controlled trial.
UK teaching hospital.
90 primigravid women with 63-91 days amenorrhoea and ultrasonically confirmed single living fetus of correct size for gestational age.
The women were allocated to receive 200 mg mifepristone orally or an identical oral placebo 36 h before operation or 1 mg gemeprost vaginal pessary 3-4 h preoperatively.
Onset of new symptoms following drug administration, a proven objective measure of the force required to dilate the cervix, and estimated intraoperative blood loss.
There were no significant differences in the baseline cervical dilatation, the force required to dilate the cervix or the volume of intraoperative blood loss between the active treatment groups. Both drugs were significantly more effective than placebo. Significantly fewer women in the mifepristone group had adverse side effects than in the gemeprost group.
Mifepristone is a highly effective cervical priming agent, and has the advantages of being an oral preparation associated with few side effects.
比较200毫克米非司酮与1毫克吉美前列素阴道栓剂在孕早期妊娠负压吸引术前使宫颈扩张和软化（“预处理”）的效果。
一项随机、术者盲法、安慰剂对照试验。
英国教学医院。
90名初孕妇，停经63 - 91天，超声确认单活胎，胎儿大小与孕周相符。
将这些妇女分为三组，分别在手术前36小时口服200毫克米非司酮或相同的口服安慰剂；或在术前3 - 4小时使用1毫克吉美前列素阴道栓剂。
给药后新症状出现情况、测量宫颈扩张所需力量的客观指标以及估计术中失血量。
活性治疗组之间在基线宫颈扩张、宫颈扩张所需力量或术中失血量方面无显著差异，但两种药物均比安慰剂显著有效。米非司酮组出现不良副作用的女性明显少于吉美前列素组
米非司酮是一种高效宫颈预处理药物，具有口服制剂且副作用少的优点。
